Literature DB >> 35076818

Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy.

Shuichi Morizane1, Masashi Honda2, Ryutaro Shimizu1, Panagiota Tsounapi1, Shogo Teraoka1, Tetsuya Yumioka1, Noriya Yamaguchi1, Bunya Kawamoto1, Hideto Iwamoto1, Katsuya Hikita1, Atsushi Takenaka1.   

Abstract

BACKGROUND: We investigated the effect of the extent of pelvic lymph node dissection (LND) on biochemical recurrence (BCR) in patients with prostate cancer (PCa) without lymph node involvement (LNI) treated with robot-assisted radical prostatectomy (RARP).
METHODS: We retrospectively analyzed data from 378 patients who underwent RARP with LND at our hospital between October 2010 and June 2019. The BCR-free survival rate was determined using Kaplan-Meier analysis, and Cox regression analysis was used to investigate BCR prognostic factors. The total score calculated from the D'Amico risk classification and the percentage of positive biopsy cores were used for analysis. Patients were classified into 3 BCR risk groups (low risk: 0-3 points, intermediate risk: 4-5 points, and high risk: 6-8 points).
RESULTS: Limited LND was performed in 161 patients (42.6%), extended LND in 217 patients (57.4%), and BCR was confirmed in 66 patients (17.5%) after RARP. Both univariate and multivariate analyses showed no significant difference in the association between the extent of LND and BCR. The Kaplan-Meier curve for BCR generated using our risk classification for patients with PCa without LNI showed no significant association between the extent of LND and BCR in the low-risk group (p = 0.790). A significantly improved BCR-free survival was observed in the extended LND group among patients with PCa at intermediate risk or higher (p < 0.05).
CONCLUSION: According to our risk classification, BCR may be less likely to occur when extended LND is performed during RARP for patients with localized PCa at intermediate risk or higher.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Biochemical recurrence; Lymph node dissection; Prostate cancer; Radical prostatectomy; Robotics

Mesh:

Year:  2022        PMID: 35076818     DOI: 10.1007/s10147-022-02121-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.

Authors:  Avinash Chenam; Nora Ruel; Sumanta Pal; John Barlog; Clayton Lau; Timothy Wilson; Bertram Yuh
Journal:  Can J Urol       Date:  2018-06       Impact factor: 1.344

2.  Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.

Authors:  Ryutaro Shimizu; Masashi Honda; Shogo Teraoka; Tetsuya Yumioka; Noriya Yamaguchi; Bunya Kawamoto; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2021-10-04       Impact factor: 3.402

  2 in total
  2 in total

1.  Prognostic Impact of Lymphatic Invasion in Patients with High-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy and Extended Lymph Node Dissection: A Single-Institution Prospective Cohort Study.

Authors:  Shimpei Yamashita; Satoshi Muraoka; Takahito Wakamiya; Kazuro Kikkawa; Yasuo Kohjimoto; Isao Hara
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

2.  The survival benefit of different lymph node yields in radical prostatectomy for pN1M0 prostate cancer patients: Implications from a population-based study.

Authors:  Jieping Hu; Yue Yu; Wei Liu; Jialei Zhong; Xiaochen Zhou; Haibo Xi
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.